Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GR1401
- Development stage
- Phase 1
- Lead developer
- Zhixiang Jintai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
GR1401 is a monoclonal antibody currently undergoing a Phase I clinical study. It is being investigated for its tolerability, pharmacokinetics, immunogenicity, safety, and preliminary efficacy in patients diagnosed with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, head and neck cancer, and esophageal cancer. The drug is being developed by Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Beyond the preview
Go deeper on GR1401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GR1401.